Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetic and Safety Trial of Intravenous Levetiracetam in the Treatment of Neonatal Seizures

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Newborns admitted to the UCSD, Children's Hospital or Sharp Mary Birch NICUs with seizures.~* Term infants (gestational age greater than or equal to 37 weeks.~* \> 2500 grams (max blood for study 6mL =3%).~* Postnatal age 14 days or less.~* Serum creatinine less than 1.2 at time of enrollment.~* Received loading dose of phenobarbital 20mg/kg.~* Are still experiencing either clinical or electroencephalographic seizures despite this therapy.~* For whom parental consent to participate in the study is obtained.~Exclusion Criteria:~* Biochemical abnormality - hypoglycemia, hypocalcemia-that when treated result in seizure cessation.~* Severe hypoxic ischemic injury likely to result in imminent death~* The only significant exclusions that will be made in recruitment and enrollment will be the exclusion of infants who are judged by the attending neonatologist to be so critically ill that death is imminent and benefit from neonatal intensive care is very unlikely.~* No rule-based criteria, (using lab or clinical parameters) adequately capture the complete nature of this clinical assessment.~* In general any child receiving active treatment with head cooling will not be excluded.~* Mechanical ventilation and/or the use of inotropic agents to support blood pressure will not be exclusion criteria.

- Gender: ALL
- Minimum Age: 1 Minute
- Maximum Age: 14 Days
- Healthy Volunteers: f

Study Arms:
- levetiracetam dose escalation (Type: EXPERIMENTAL): 6 Babies in Phase 1-Received Dose 1: 20 mg/kg; 5 mg/kg daily 12 Babies in Phase 2-Received Dose 2: 40 mg/kg; 10 mg/kg/day

Based on this trial design, predict the completion outcome and termination type (if applicable).